#United States #New York #Class Action #Pomerantz LLP #Biohaven Ltd

Pomerantz Law Firm Takes Action Against Biohaven Ltd.

In a significant move, Pomerantz LLP has announced the filing of a class action lawsuit against Biohaven Ltd. (NYSE: BHVN), along with several of its key officers. This litigation, which is being carried out in the United States District Court for the District of Connecticut under docket number 25-cv-01120, represents a collective effort by individuals and groups who purchased or otherwise acquired Biohaven securities during a specific period — from March 24, 2023, to May 14, 2025, inclusive.

The allegations center around violations of federal securities laws, with the aim of seeking restitution for damages incurred by investors due to the actions of the defendants. The law firm is calling on affected shareholders to step forward and consider their options to join this important initiative, providing them until September 12, 2025, to file as Lead Plaintiffs.

Background on Biohaven Ltd.

Biohaven Ltd. is recognized in the biopharmaceutical sector for developing innovative therapies targeted at conditions involving immunology, neuroscience, and oncology. The company has several product candidates in its pipeline, notably including `troriluzole`, which is aimed at treating spinocerebellar ataxia (SCA), and `BHV-7000` for treating bipolar disorder.

Despite Biohaven’s promising portfolio, concerns were raised when a Phase 3 trial testing the efficacy of troriluzole for SCA failed to meet its primary endpoints in May 2022. Nonetheless, through subsequent months, company executives continued to promote the drug's potential, citing positive data from post-hoc analyses that many investors believed misrepresented the drug's prospects.

In May 2023, Biohaven made headlines by submitting a New Drug Application (NDA) for troriluzole to the FDA. This was followed by the European Medicines Agency's (EMA) acceptance of a Marketing Authorization Application (MAA) in October 2023, keeping hopes alive for investors. However, a series of negative revelations about the company's drugs began to surface, leading to significant stock price fluctuations.

Key Developments and Stock Market Reactions

On July 27, 2023, the FDA announced its rejection of the troriluzole NDA, primarily due to disappointing results from the Phase 3 trial. Following this announcement, Biohaven's shares plummeted by over 22%, indicating investor disappointment and loss of confidence. In the months that followed, the stock continued to face headwinds, dropping further due to adverse market reactions to subsequent announcements about clinical trials and regulatory setbacks.

On December 16, 2024, Biohaven revealed it had refiled the NDA for troriluzole, citing new efficacy data, yet further disappointing news arrived on March 3, 2025, with disclosures regarding the clinical prospects of BHV-7000, which again fell short. Such incidences fueled skepticism about the transparency of the company’s messaging and its professed business viability.

Adding to the challenges, reports emerged in late April 2025 that Biohaven had withdrawn its MAA for troriluzole from the EMA, resulting in another sharp decline in stock value.

The timeline of events underscores a troubling pattern regarding the accuracy of public statements made by Biohaven’s officers. Investors now find themselves grappling with the ramifications of these alleged misrepresentations, which are central to the class action suit brought forth by Pomerantz LLP.

Conclusion and Next Steps for Investors

Pomerantz LLP, which has a longstanding reputation in handling corporate, securities, and antitrust class actions, is leading this case with the goal of addressing the injustices faced by shareholders. Interested individuals are urged to consult with the firm for further details on how to join the class action and represent their rights as investors.

The law firm’s extensive experience in recovering damages for class members positions them as a formidable advocate for those impacted by corporate misconduct.

For more information or to pursue action, prospective plaintiffs can visit Pomerantz Law Firm’s website or contact Danielle Peyton directly at 646-581-9980.